Abstract
Background: Sofosbuvir is a direct-acting antiviral drug used to treat chronic hepatitis C infection. In 2015, Gilead Sciences, the manufacturer of sofosbuvir, warned that bradycardia could occur when sofosbuvir is administered in combination with amiodarone. Interestingly, among the reported cases of patients with sofosbuvir and amiodarone related bradycardia, some of them were also treated with propranolol.
Objective: We herein report a case of ventricular extrasystoles within three hours after the coadministration of sofosbuvir-containing regimen with propranolol. This patient had never been treated with amiodarone. After the sofosbuvir-containing regimen was stopped, ventricular extrasystoles disappeared within 24 hours. This observation suggests that the association of sofosbuvir with propranolol may have a role in the emergence of cardiac arrhythmia.
Conclusion: Patients treated with amiodarone and/or propranolol should be continuously monitored within the early hours following the initiation of sofosbuvir.
Keywords: Cardiac arrhythmia, drug interaction, extrasystole, Hepatitis C, propranolol, sofosbuvir.
Graphical Abstract
Reviews on Recent Clinical Trials
Title:Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report
Volume: 12 Issue: 3
Author(s): Samir Rouabhia*, Sabah Baghazza, Hamza Sadouki, Sihem Djezzar, Rafik Bencherif, Rofia Guehimeche, Mourad Sadelaoud, Djamel Mallem and Karima Chaabna
Affiliation:
- Department of Internal Medicine, University Hospital Center Touhami Benflis, Batna 05000, Algeria and Department of Medicine, University Batna 2, Batna 05000,Algeria
Keywords: Cardiac arrhythmia, drug interaction, extrasystole, Hepatitis C, propranolol, sofosbuvir.
Abstract: Background: Sofosbuvir is a direct-acting antiviral drug used to treat chronic hepatitis C infection. In 2015, Gilead Sciences, the manufacturer of sofosbuvir, warned that bradycardia could occur when sofosbuvir is administered in combination with amiodarone. Interestingly, among the reported cases of patients with sofosbuvir and amiodarone related bradycardia, some of them were also treated with propranolol.
Objective: We herein report a case of ventricular extrasystoles within three hours after the coadministration of sofosbuvir-containing regimen with propranolol. This patient had never been treated with amiodarone. After the sofosbuvir-containing regimen was stopped, ventricular extrasystoles disappeared within 24 hours. This observation suggests that the association of sofosbuvir with propranolol may have a role in the emergence of cardiac arrhythmia.
Conclusion: Patients treated with amiodarone and/or propranolol should be continuously monitored within the early hours following the initiation of sofosbuvir.
Export Options
About this article
Cite this article as:
Rouabhia Samir *, Baghazza Sabah , Sadouki Hamza, Djezzar Sihem , Bencherif Rafik, Guehimeche Rofia , Sadelaoud Mourad, Mallem Djamel and Chaabna Karima, Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report, Reviews on Recent Clinical Trials 2017; 12 (3) . https://dx.doi.org/10.2174/1574887112666170725132044
DOI https://dx.doi.org/10.2174/1574887112666170725132044 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Editorial [Hot Topic: Prebiotics and Probiotics: Delivering Therapeutics as Dietary Components (Executive Editor: Colum Dunne)]
Current Pharmaceutical Design Synthesis and Binding Properties of New Endothelin Receptor Ligands
Letters in Drug Design & Discovery Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Monoamine Oxidases: to Inhibit or Not to Inhibit
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Transportalopathy and Vascular Cell Dysfunction (Guest Editor: Luis Sobrevia)]
Current Vascular Pharmacology The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation
Current Vascular Pharmacology Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Microwave-Promoted One-Pot Three-Component Synthesis of 1-Amidoalkyl-2-Carbazolol Derivatives
Letters in Organic Chemistry Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia
Current Molecular Medicine Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Current Pharmaceutical Design Glucose Intolerance and Diabetes Mellitus in Endocrine Disorders – Two Case Reports and a Review
Current Diabetes Reviews Adipokines as Potential Biomarkers in the Neurorehabilitation of Obese Stroke Patients
Current Neurovascular Research Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Nonalcoholic fatty liver disease in children and adolescents – Relationship with Polycystic Ovary Syndrome
Current Pharmaceutical Design